Neuronal nicotinic acetylcholine receptors as pharmacotherapeutic targets for the treatment of alcohol use disorders

CNS and Neurological Disorders - Drug Targets

Volumn 9, Issue 1, 2010, Pages 60-76

  Chatterjee, S ^a   Bartlett, S E ^a  

^a UNIVERSITY OF CALIFORNIA SAN FRANCISCO   (United States)

Author keywords

Ethanol; Mecamylamine; nAChRs; Nicotine; Pharmacotherapy; Smoking cessation aids; Varenicline

Indexed keywords

ACAMPROSATE; ALCOHOL; ANTIEMETIC AGENT; ION CHANNEL; LY 686017; MECAMYLAMINE; NALTREXONE; NEUROKININ 1 RECEPTOR ANTAGONIST; NICOTINE; NICOTINIC RECEPTOR; UNCLASSIFIED DRUG; VARENICLINE;

ALCOHOL WITHDRAWAL; ALCOHOLISM; BEHAVIOR THERAPY; CLINICAL DECISION MAKING; CLINICAL EVALUATION; CLINICAL TRIAL; COMPARATIVE STUDY; CONSTIPATION; DEPRESSION; DOPAMINE RELEASE; DROWSINESS; DRUG DEPENDENCE; DRUG EFFECT; DRUG SAFETY; DRUG SELF ADMINISTRATION; DRUG THERAPY; DRUG TOLERABILITY; DRY SKIN; GENETIC SUSCEPTIBILITY; HUMAN; MENTAL DISEASE; MULTIMODALITY CANCER THERAPY; MYDRIASIS; NEUROMODULATION; NONHUMAN; RECURRENT DISEASE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; SMOKING CESSATION; SUICIDE ATTEMPT; TARGET VARIABLE; TECHNICAL AID; TREATMENT OUTCOME; URINE RETENTION; XEROSTOMIA;

EID: 77949905566     PISSN: 18715273     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152710790966597     Document Type: Review

References (295)

1. Arolfo, M.P.; Yao, L.; Gordon, A.S.; Diamond, I.; Janak, P.H. Ethanol operant self-administration in rats is regulated by adenosine A2 receptors. Alcohol. Clin. Exp. Res., 2004, 28, 1308-1316.
2. Bailey, C.P.; O'Callaghan, M.J.; Croft, A.P.; Manley, S.J.; Little, H.J. Alterations in mesolimbic dopamine function during the abstinence period following chronic ethanol consumption. Neuropharmacology, 2001, 41, 989-999.
3. Bainton, R.J.; Tsai, L.T.; Singh, C.M.; Moore, M.S.; Neckameyer, W.S.; Heberlein, U. Dopamine modulates acute responses to cocaine, nicotine and ethanol in Drosophila. Curr. Biol., 2000, 10, 187-194.
4. Becker, A.; Grecksch, G.; Kraus, J.; Loh, H.H.; Schroeder, H.; Hollt, V. Rewarding effects of ethanol and cocaine in mu opioid receptor-deficient mice. Naunyn-Schmiedebergs Arch. Pharmacol., 2002, 365, 296-302.
5. Bisaga, A.; Sikora, J.; Kostowski, W. The effect of drugs interacting with serotonergic 5HT3 and 5HT4 receptors on morphine place conditioning. Pol. J. Pharmacol., 1993, 45, 513-519.
6. Borg, P.J.; Taylor, D.A. Involvement of mu- and delta-opioid receptors in the effects of systemic and locally perfused morphine on extracellular levels of dopamine, DOPAC and HVA in the nucleus accumbens of the halothane- anaesthetized rat. Naunyn-Schmiedebergs Arch. Pharmacol., 1997, 355, 582-588.
7. Brodie, M.S. Increased ethanol excitation of dopaminergic neurons of the ventral tegmental area after chronic ethanol treatment. Alcohol. Clin. Exp. Res., 2002, 26, 1024-1030.
8. Charness, M.E.; Simon, R.P.; Greenberg, D.A. Ethanol and the nervous system. N. Engl. J. Med., 1989, 321, 442-454.
9. Davis, T.J.; de Fiebre, C.M. Alcohol's actions on neuronal nicotinic acetylcholine receptors. Alcohol Res. Health, 2006, 29, 179-185.
10. Doyon, W.M.; York, J.L.; Diaz, L.M.; Samson, H.H.; Czachowski, C.L.; Gonzales, R.A. Dopamine activity in the nucleus accumbens during consummatory phases of oral ethanol self-administration. Alcohol. Clin. Exp. Res., 2003, 27, 1573-1582.
11. Froehlich, J.C.; Zweifel, M.; Harts, J.; Lumeng, L.; Li, T.K. Importance of delta opioid receptors in maintaining high alcohol drinking. Psychopharmacology (Berl), 1991, 103, 467-472.
12. A receptor modulators and alcohol in mice lacking PKCe. Nat. Neurosci., 1999, 2, 997-1002.
13. Hoffman, P.L.; Urwyler, S.; Tabakoff, B. Alterations in opiate receptor function after chronic ethanol exposure. J. Pharmacol. Exp. Ther., 1982, 222, 182-189.
14. Janak, P.H.; Wolf, F.W.; Heberlein, U.; Pandey, S.C.; Logrip, M.L.; Ron, D. BIG news in alcohol addiction: new findings on growth factor pathways BDNF, insulin, and GDNF. Alcohol. Clin. Exp. Res., 2006, 30, 214-221.
15. Le, A.D.; Wang, A.; Harding, S.; Juzytsch, W.; Shaham, Y. Nicotine increases alcohol self-administration and reinstates alcohol seeking in rats. Psychopharmacology (Berl), 2003, 168, 216-221.
16. Matsuzawa, S.; Suzuki, T.; Misawa, M.; Nagase, H. Different roles of mu-, delta- and kappa-opioid receptors in ethanol-associated place preference in rats exposed to conditioned fear stress. Eur. J. Pharmacol., 1999, 368, 9-16.
17. B agonist baclofen on the temporal and structural characteristics of ethanol intake. Alcohol, 1999, 17, 231-240.
18. Smith, B.R.; Horan, J.T.; Gaskin, S.; Amit, Z. Exposure to nicotine enhances acquisition of ethanol drinking by laboratory rats in a limited access paradigm. Psychopharmacology (Berl), 1999, 142, 408-412.
19. Steensland, P.; Simms, J.A.; Holgate, J.; Richards, J.K.; Bartlett, S.E. Varenicline, an a4b2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking. Proc. Natl. Acad. Sci. USA, 2007, 104, 12518-12523.
20. Nielsen, C.K.; Simms, J.A.; Pierson, H.B.; Li, R.; Saini, S.K.; Ananthan, S.; Bartlett, S.E. A novel delta opioid receptor antagonist, SoRI-9409, produces a selective and long-lasting decrease in ethanol consumption in heavy-drinking rats. Biol. Psychiatry, 2008, 64, 974-981.
21. Richards, J.K.; Simms, J.A.; Steensland, P.; Taha, S.A.; Borgland, S.L.; Bonci, A.; Bartlett, S.E. Inhibition of orexin-1/hypocretin-1 receptors inhibits yohimbine-induced reinstatement of ethanol and sucrose seeking in Long-Evans rats. Psychopharmacology (Berl), 2008, 199, 109-117.
22. Vengeliene, V.; Bilbao, A.; Molander, A.; Spanagel, R. Neuropharmacology of alcohol addiction. Br. J. Pharmacol., 2008, 154, 299-315.
23. Spanagel, R. Alcoholism: a systems approach from molecular physiology to addictive behavior. Physiol. Rev., 2009, 89, 649-705.
24. Istvan, J.; Matarazzo, J.D. Tobacco, alcohol, and caffeine use: a review of their interrelationships. Psychol. Bull., 1984, 95, 301-326.
25. Sobell, L.C.; Sobell, M.B.; Kozlowski, L.T.; Toneatto, T. Alcohol or tobacco research versus alcohol and tobacco research. Br. J. Addict.,1990, 85, 263-269.
26. Falk, D.E.; Yi, H.Y.; Hiller-Sturmhofel, S. An epidemiologic analysis of co-occurring alcohol and tobacco use and disorders: findings from the national epidemiologic survey on alcohol and related conditions. Alcohol Res. Health, 2006, 29, 162-171.
27. Potthoff, A.D.; Ellison, G.; Nelson, L. Ethanol intake increases during continuous administration of amphetamine and nicotine, but not several other drugs. Pharmacol. Biochem. Behav., 1983, 18, 489-493.
28. Blomqvist, O.; Ericson, M.; Johnson, D.H.; Engel, J.A.; Soderpalm, B. Voluntary ethanol intake in the rat: effects of nicotinic acetylcholine receptor blockade or subchronic nicotine treatment. Eur. J. Pharmacol., 1996, 314, 257-267.
29. Clark, A.; Lindgren, S.; Brooks, S.P.; Watson, W.P.; Little, H. J. Chronic infusion of nicotine can increase operant self-administration of alcohol. Neuropharmacology, 2001, 41, 108-117.
30. Le, A.D.; Corrigall, W.A.; Harding, J.W.; Juzytsch, W.; Li, T.K. Involvement of nicotinic receptors in alcohol self-administration. Alcohol. Clin. Exp. Res., 2000, 24, 155-163.
31. Olausson, P.; Ericson, M.; Lof, E.; Engel, J.A.; Soderpalm, B. Nicotine-induced behavioral disinhibition and ethanol preference correlate after repeated nicotine treatment. Eur. J. Pharmacol., 2001, 417, 117-123.
32. Rose, J.E.; Behm, F.M.; Westman, E.C.; Levin, E.D.; Stein, R.M.; Ripka, G.V. Mecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment alone. Clin. Pharmacol. Ther., 1994, 56, 86-99.
33. Rose, J.E.; Behm, F.M.; Westman, E.C. Nicotine-mecamylamine treatment for smoking cessation: the role of pre-cessation therapy. Exp. Clin. Psychopharmacol.,1998, 6, 331-343.
34. 2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA, 2006, 296, 56-63.
35. 2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA, 2006, 296, 47-55.
36. Babor, T.F.; Hofmann, M.; DelBoca, F.K.; Hesselbrock, V.; Meyer, R.E.; Dolinsky, Z.S.; Rounsaville, B. Types of alcoholics, I. Evidence for an empirically derived typology based on indicators of vulnerability and severity. Arch. Gen. Psychiatry, 1992, 49, 599-608.
37. Cloninger, C.R.; Bohman, M.; Sigvardsson, S. Inheritance of alcohol abuse. Cross-fostering analysis of adopted men. Arch. Gen. Psychiatry, 1981, 38, 861-868.
38. Lesch, O.M.; Dietzel, M.; Musalek, M.; Walter, H.; Zeiler, K. The course of alcoholism. Long-term prognosis in different types. Forensic Sci. Intl., 1988, 36, 121-138.
39. Jacob, T.; Bucholz, K.K.; Sartor, C.E.; Howell, D.N.; Wood, P.K. Drinking trajectories from adolescence to the mid-forties among alcohol dependent males. J. Stud. Alcohol. 2005, 66, 745-755.
40. Moss, H.B.; Chen, C.M.; Yi, H.Y. Subtypes of alcohol dependence in a nationally representative sample. Drug Alcohol Depend., 2007, 91, 149-158.
41. Windle, M.; Scheidt, D.M. Alcoholic subtypes: are two sufficient? Addiction, 2004, 99, 1508-1519.
42. Bohman, M.; Wennberg, P.; Andersson, T. Alcohol habits in a suburban male cohort. Scand. J. Public Health, 2000, 28, 275-282.
43. Chung, T.; Martin, C.S. Classification and course of alcohol problems among adolescents in addictions treatment programs. Alcohol. Clin. Exp. Res., 2001, 25, 1734-1742.
44. Zucker, R.A.; Davies, W.H.; Kincaid, S.B.; Fitzgerald, H.E.; Reider, E.E. Conceptualizing and scaling the developmental structure of behavior disorder: the lifetime alcohol problems score as an example. Dev. Psychopathol., 1997, 9, 453-471.
45. Dawson, D.A.; Grant, B.F.; Stinson, F.S.; Chou, P.S.; Huang, B.; Ruan, W.J. Recovery from DSM-IV alcohol dependence: United States, 2001-2002. Addiction, 2005, 100, 281-292.
46. Hurt, R.D.; Eberman, K.M.; Croghan, I.T.; Offord, K.P.; Davis, L.J., Jr.; Morse, R.M.; Palmen, M.A.; Bruce, B.K. Nicotine dependence treatment during inpatient treatment for other addictions: a prospective intervention trial. Alcohol. Clin. Exp. Res., 1994, 18, 867-872.
47. Grant, B.F. Age at smoking onset and its association with alcohol consumption and DSM-IV alcohol abuse and dependence: results from the national longitudinal alcohol epidemiologic survey. J. Subs. Abuse, 1998, 10, 59-73.
48. Schlaepfer, I.R.; Hoft, N.R.; Ehringer, M.A. The genetic components of alcohol and nicotine co-addiction: from genes to behavior. Curr. Drug Abuse Rev., 2008, 1, 124-134.
49. Stolerman, I.P.; Garcha, H.S.; Mirza, N.R. Dissociations between the locomotor stimulant and depressant effects of nicotinic agonists in rats. Psychopharmacology (Berl), 1995, 117, 430-437.
50. Stolerman, I.P.; Fink, R.; Jarvik, M.E. Acute and chronic tolerance to nicotine measured by activity in rats. Psychopharmacologia, 1973, 30, 329-342.
51. Signs, S.A.; Schechter, M.D. Nicotine-induced potentiation of ethanol discrimination. Pharmacol. Biochem. Behav., 1986, 24, 769-771.
52. Ericson, M.; Lof, E.; Stomberg, R.; Soderpalm, B. The smoking cessation medication varenicline attenuates alcohol and nicotine interactions in the rat mesolimbic dopamine system. J. Pharmacol. Exp. Ther., 2009, 329(1), 225-230.
53. Tizabi, Y.; Bai, L.; Copeland, R.L., Jr.; Taylor, R.E. Combined effects of systemic alcohol and nicotine on dopamine release in the nucleus accumbens shell. Alcohol Alcohol., 2007, 42, 413-416.
54. Tizabi, Y.; Copeland, R.L., Jr.; Louis, V.A.; Taylor, R.E. Effects of combined systemic alcohol and central nicotine administration into ventral tegmental area on dopamine release in the nucleus accumbens. Alcohol. Clin. Exp. Res., 2002, 26, 394-399.
55. Clark, A.; Little, H.J. Interactions between low concentrations of ethanol and nicotine on firing rate of ventral tegmental dopamine neurones. Drug Alcohol Depend., 2004, 75, 199-206.
56. Koob, G.F.; Bloom, F.E. Cellular and molecular mechanisms of drug dependence. Science, 1988, 242, 715-723.
57. Wise, R.A.; Rompre, P.P. Brain dopamine and reward. Annu. Rev. Psychol., 1989, 40, 191-225.
58. Di Chiara, G.; Imperato, A. Ethanol preferentially stimulates dopamine release in the nucleus accumbens of freely moving rats. Eur. J. Pharmacol., 1985, 115, 131-112.
59. Marszalec, W.; Aistrup, G.L.; Narahashi, T. Ethanol-nicotine interactions at a-bungarotoxin-insensitive nicotinic acetylcholine receptors in rat cortical neurons. Alcohol. Clin. Exp. Res., 1999, 23, 439-445.
60. Marks, M.J.; Burch, J.B.; Collins, A.C. Effects of chronic nicotine infusion on tolerance development and nicotinic receptors. J. Pharmacol. Exp. Ther., 1983, 226, 817-825.
61. 3H-nicotinic binding in rat brain. Naunyn-Schmied. Arch. Pharmacol., 1982, 321, 74-76.
62. Collins, A.C.; Wilkins, L.H.; Slobe, B.S.; Cao, J.Z.; Bullock, A.E. Long-term ethanol and nicotine treatment elicit tolerance to ethanol. Alcohol. Clin. Exp. Res., 1996, 20, 990-999.
63. Al-Rejaie, S.; Dar, M.S. Antagonism of ethanol ataxia by intracerebellar nicotine: possible modulation by mouse cerebellar nitric oxide and cGMP. Brain Res. Bull., 2006, 69, 187-196.
64. Gould, T.J.; Lommock, J.A. Nicotine enhances contextual fear conditioning and ameliorates ethanol-induced deficits in contextual fear conditioning. Behav. Neurosci., 2003, 117, 1276-1282.
65. Gould, T.J.; Collins, A.C.; Wehner, J.M. Nicotine enhances latent inhibition and ameliorates ethanol-induced deficits in latent inhibition. Nicotine Tob. Res., 2001, 3, 17-24.
66. Melia, K.R.; Ryabinin, A.E.; Corodimas, K.P.; Wilson, M.C.; Ledoux, J.E. Hippocampal-dependent learning and experience-dependent activation of the hippocampus are preferentially disrupted by ethanol. Neuroscience, 1996, 74, 313-322.
67. Butt, C.M.; King, N.M.; Stitzel, J.A.; Collins, A.C. Interaction of the nicotinic cholinergic system with ethanol withdrawal. J. Pharmacol. Exp. Ther., 2004, 308, 591-599.
68. Ceballos, N.A.; Tivis, R.; Lawton-Craddock, A.; Nixond, S.J. Nicotine and cognitive efficiency in alcoholics and illicit stimulant abusers: implications of smoking cessation for substance users in treatment. Subst. Use Misuse, 2006, 41, 265-281.
69. Tizabi, Y.; Manaye, K.F.; Smoot, D.T.; Taylor, R.E. Nicotine inhibits ethanol-induced toxicity in cultured cerebral cortical cells. Neurotox. Res. 2004, 6, 311-316.
70. Tizabi, Y.; Al-Namaeh, M.; Manaye, K.F.; Taylor, R.E. Protective effects of nicotine on ethanol-induced toxicity in cultured cerebellar granule cells. Neurotox. Res. 2003, 5, 315-321.
71. Collins, A.C.; Romm, E.; Selvaag, S.; Turner, S.; Marks, M.J. A comparison of the effects of chronic nicotine infusion on tolerance to nicotine and cross-tolerance to ethanol in long- and short-sleep mice. J. Pharmacol. Exp. Ther., 1993, 266, 1390-1397.
72. Collins, A.C.; Burch, J.B.; de Fiebre, C.M.; Marks, M.J. Tolerance to and cross tolerance between ethanol and nicotine. Pharmacol. Biochem. Behav., 1988, 29, 365-373.
73. de Fiebre, C.M.; Collins, A.C. A comparison of the development of tolerance to ethanol and cross-tolerance to nicotine after chronic ethanol treatment in long- and short-sleep mice. J. Pharmacol. Exp. Ther., 1993, 266, 1398-1406.
74. Burch, J.B.; de Fiebre, C.M.; Marks, M.J.; Collins, A.C. Chronic ethanol or nicotine treatment results in partial cross-tolerance between these agents. Psychopharmacology (Berl), 1988, 95, 452-458.
75. de Fiebre, C.M.; Marks, M.J.; Collins, A.C. Ethanol-nicotine interactions in long-sleep and short-sleep mice. Alcohol, 1990, 7, 249-257.
76. Zacny, J.P. Behavioral aspects of alcohol-tobacco interactions. Recent Dev. Alcohol., 1990, 8, 205-219.
77. Bierut, L.J.; Schuckit, M.A.; Hesselbrock, V.; Reich, T. Co-occurring risk factors for alcohol dependence and habitual smoking. Alcohol Res. Health., 2000, 24, 233-241.
78. Madden, P.A.; Heath, A.C. Shared genetic vulnerability in alcohol and cigarette use and dependence. Alcohol. Clin. Exp. Res., 2002, 26, 1919-1921.
79. True, W.R.; Xian, H.; Scherrer, J.F.; Madden, P.A.; Bucholz, K.K.; Heath, A.C.; Eisen, S.A.; Lyons, M.J.; Goldberg, J.; Tsuang, M. Common genetic vulnerability for nicotine and alcohol dependence in men. Arch. Gen. Psychiatry, 1999, 56, 655-661.
80. Heath, A.C.; Bucholz, K.K.; Madden, P.A.; Dinwiddie, S.H.; Slutske, W.S.; Bierut, L.J.; Statham, D.J.; Dunne, M.P.; Whitfield, J.B.; Martin, N.G. Genetic and environmental contributions to alcohol dependence risk in a national twin sample: consistency of findings in women and men. Psychol. Med., 1997, 27, 1381-1396.
81. Bierut, L.J.; Stitzel, J.A.; Wang, J.C.; Hinrichs, A.L.; Grucza, R.A.; Xuei, X.; Saccone, N.L.; Saccone, S.F.; Bertelsen, S.; Fox, L.; Horton, W.J.; Breslau, N.; Budde, J.; Cloninger, C.R.; Dick, D.M.; Foroud, T.; Hatsukami, D.; Hesselbrock, V.; Johnson, E.O.; Kramer, J.; Kuperman, S.; Madden, P.A.; Mayo, K.; Nurnberger, J., Jr.; Pomerleau, O.; Porjesz, B.; Reyes, O.; Schuckit, M.; Swan, G.; Tischfield, J.A.; Edenberg, H.J.; Rice, J.P.; Goate, A.M. Variants in nicotinic receptors and risk for nicotine dependence. Am. J. Psychiatry, 2008, 165, 1163-1171.
82. Chen, X.; Chen, J.; Williamson, V.S.; An, S.S.; Hettema, J.M.; Aggen, S.H.; Neale, M.C.; Kendler, K.S. Variants in nicotinic acetylcholine receptors a5 and a3 increase risks to nicotine dependence. Am. J. Med. Genet. B Neuropsychiatr. Genet., 2009, 150B(7), 926-933..
83. Grucza, R.A.; Wang, J.C.; Stitzel, J.A.; Hinrichs, A.L.; Saccone, S.F.; Saccone, N.L.; Bucholz, K.K.; Cloninger, C.R.; Neuman, R.J.; Budde, J.P.; Fox, L.; Bertelsen, S.; Kramer, J.; Hesselbrock, V.; Tischfield, J.; Nurnberger, J.I., Jr.; Almasy, L.; Porjesz, B.; Kuperman, S.; Schuckit, M.A.; Edenberg, H.J.; Rice, J.P.; Goate, A.M.; Bierut, L.J. A risk allele for nicotine dependence in CHRNA5 is a protective allele for cocaine dependence. Biol. Psychiatry, 2008, 64, 922-929.
84. Saccone, N.L.; Saccone, S.F.; Hinrichs, A.L.; Stitzel, J.A.; Duan, W.; Pergadia, M.L.; Agrawal, A.; Breslau, N.; Grucza, R.A.; Hatsukami, D.; Johnson, E.O.; Madden, P.A.; Swan, G.E.; Wang, J.C.; Goate, A.M.; Rice, J.P.; Bierut, L.J. Multiple distinct risk loci for nicotine dependence identified by dense coverage of the complete family of nicotinic receptor subunit (CHRN) genes. Am. J. Med. Genet. B Neuropsychiatr. Genet., 150B(4), 453-466.
85. Wang, J.C.; Grucza, R.; Cruchaga, C.; Hinrichs, A.L.; Bertelsen, S.; Budde, J.P.; Fox, L.; Goldstein, E.; Reyes, O.; Saccone, N.; Saccone, S.; Xuei, X.; Bucholz, K.; Kuperman, S.; Nurnberger, J., Jr.; Rice, J.P.; Schuckit, M.; Tischfield, J.; Hesselbrock, V.; Porjesz, B.; Edenberg, H.J.; Bierut, L.J.; Goate, A.M. Genetic variation in the CHRNA5 gene affects mRNA levels and is associated with risk for alcohol dependence. Mol. Psychiatry, 2009, 14, 501-510.
86. Joslyn, G.; Brush, G.; Robertson, M.; Smith, T.L.; Kalmijn, J.; Schuckit, M.; White, R.L. Chromosome 15q25.1 genetic markers associated with level of response to alcohol in humans. Proc. Natl. Acad. Sci. U.S.A., 2008, 105, 20368-20373.
87. Stevens, V.L.; Bierut, L.J.; Talbot, J.T.; Wang, J.C.; Sun, J.; Hinrichs, A.L.; Thun, M.J.; Goate, A.; Calle, E.E. Nicotinic receptor gene variants influence susceptibility to heavy smoking. Cancer Epidemiol. Biomarkers Prev., 2008, 17, 3517-3525.
88. Kamens, H.M.; McKinnon, C.S.; Li, N.; Helms, M.L.; Belknap, J.K.; Phillips, T.J. The a3 subunit of the nicotinic acetylcholine receptor is a candidate gene for ethanol stimulation. Genes Brain Behav., 2009 (in press).
89. Funk, D.; Marinelli, P.W.; Le, A.D. Biological processes underlying co-use of alcohol and nicotine: neuronal mechanisms, cross-tolerance, and genetic factors. Alcohol Res. Health, 2006, 29, 186-192.
90. Barrett, S.P.; Tichauer, M.; Leyton, M.; Pihl, R.O. Nicotine increases alcohol self-administration in non-dependent male smokers. Drug Alcohol Depend., 2006, 81, 197-204.
91. Marks, J.L.; Hill, E.M.; Pomerleau, C.S.; Mudd, S.A.; Blow, F.C. Nicotine dependence and withdrawal in alcoholic and nonalcoholic ever-smokers. J. Subst. Abuse Treatment, 1997, 14, 521-527.
92. Shaham, Y.; Shalev, U.; Lu, L.; De Wit, H.; Stewart, J. The reinstatement model of drug relapse: history, methodology and major findings. Psychopharmacology (Berl), 2003, 168, 3-20.
93. Perkins, K.A.; Fonte, C.; Grobe, J.E. Sex differences in the acute effects of cigarette smoking on the reinforcing value of alcohol. Behav. Pharmacol., 2000, 11, 63-70.
94. Schmidt, J.; Raftery, M.A. Purification of acetylcholine receptors from Torpedo californica electroplax by affinity chromatography. Biochemistry, 1973, 12, 852-856.
95. McNamee, M.G.; Weill, C.L.; Karlin, A. Purification of acetylcholine receptor from Torpedo californica and its incorporation into phospholipid vesicles. Ann. NY Acad. Sci., 1975, 264, 175-182.
96. Sargent, P.B. The diversity of neuronal nicotinic acetylcholine receptors. Annu. Rev. Neurosci., 1993, 16, 403-443.
97. Gotti, C.; Clementi, F.; Fornari, A.; Gaimarri, A.; Guiducci, S.; Manfredi, I.; Moretti, M.; Pedrazzi, P.; Pucci, L.; Zoli, M. Structural and functional diversity of native brain neuronal nicotinic receptors. Biochem. Pharmacol., 2009, 78, 703-711.
98. Albuquerque, E.X.; Pereira, E.F.; Alkondon, M.; Rogers, S.W. Mammalian nicotinic acetylcholine receptors: from structure to function. Physiol. Rev., 2009, 89, 73-120.
99. Luetje, C.W.; Patrick, J.; Seguela, P. Nicotine receptors in the mammalian brain. FASEB J., 1990, 4, 2753-2760.
100. Patrick, J.; Sequela, P.; Vernino, S.; Amador, M.; Luetje, C.; Dani, J. A. Functional diversity of neuronal nicotinic acetylcholine receptors. Prog. Brain Res., 1993, 98, 113-120.
101. Colquhoun, L.M.; Patrick, J.W. Pharmacology of neuronal nicotinic acetylcholine receptor subtypes. Adv. Pharmacol., 1997, 39, 191-220.
102. Champtiaux, N.; Gotti, C.; Cordero-Erausquin, M.; David, D.J.; Przybylski, C.; Lena, C.; Clementi, F.; Moretti, M.; Rossi, F.M.; Le Novere, N.; McIntosh, J.M.; Gardier, A.M.; Changeux, J.P. Subunit composition of functional nicotinic receptors in dopaminergic neurons investigated with knock-out mice. J. Neurosci., 2003, 23, 7820-7829.
103. 2 subunits and is up-regulated by chronic nicotine treatment. Mol. Pharmacol., 1992, 41, 31-37.
104. 2 mutant mice. J. Neurosci., 1998, 18, 4461-4472.
105. Le Novere, N.; Changeux, J.P. Molecular evolution of the nicotinic acetylcholine receptor: an example of multigene family in excitable cells. J. Mol. Evol., 1995, 40, 155-172.
106. Corringer, P.J.; Le Novere, N.; Changeux, J.P. Nicotinic receptors at the amino acid level. Annu. Rev. Pharmacol. Toxicol., 2000, 40, 431-458.
107. 125I]-alpha-bungarotoxin. J. Neurosci., 1985, 5, 1307-1315.
108. 3H]cytisine binding to nicotinic cholinergic receptors in brain. Mol. Pharmacol., 1991, 39, 9-12.
109. Gotti, C.; Fornasari, D.; Clementi, F. Human neuronal nicotinic receptors. Prog. Neurobiol., 1997, 53, 199-237.
110. Klink, R.; de Kerchove d'Exaerde, A.; Zoli, M.; Changeux, J.P. Molecular and physiological diversity of nicotinic acetylcholine receptors in the midbrain dopaminergic nuclei. J. Neurosci., 2001, 21, 1452-1463.
111. Zoli, M.; Moretti, M.; Zanardi, A.; McIntosh, J.M.; Clementi, F.; Gotti, C. Identification of the nicotinic receptor subtypes expressed on dopaminergic terminals in the rat striatum. J. Neurosci., 2002, 22, 8785-8789.
112. Quick, M.W.; Ceballos, R.M.; Kasten, M.; McIntosh, J.M.; Lester, R.A. a3b4 subunit-containing nicotinic receptors dominate function in rat medial habenula neurons. Neuropharmacology, 1999, 38, 769-783.
113. 4-containing nicotinic receptors in the medial habenula. Neuropharmacology, 2009, 56, 247-253.
114. Grybko, M.; Sharma, G.; Vijayaraghavan, S. Functional distribution of nicotinic receptors in CA3 region of the hippocampus. J. Mol. Neurosci., 2009 (in press).
115. 7-nicotinic receptor expression and the anatomical organization of hippocampal interneurons. Brain Res., 2001, 922, 180-190.
116. Rubboli, F.; Court, J.A.; Sala, C.; Morris, C.; Chini, B.; Perry, E.; Clementi, F. Distribution of nicotinic receptors in the human hippocampus and thalamus. Eur. J. Neurosci., 1994, 6, 1596-1604.
117. Lindstrom, J.; Schoepfer, R.; Conroy, W.G.; Whiting, P. Structural and functional heterogeneity of nicotinic receptors. Ciba Found. Symp., 1990, 152, 23-42.
118. Deneris, E.S.; Connolly, J.; Rogers, S.W.; Duvoisin, R. Pharmacological and functional diversity of neuronal nicotinic acetylcholine receptors. Trends Pharmacol. Sci., 1991, 12, 34-40.
119. Le Novere, N.; Corringer, P.J.; Changeux, J.P. The diversity of subunit composition in nAChRs: evolutionary origins, physiologic and pharmacologic consequences. J. Neurobiol., 2002, 53, 447-456.
120. Gotti, C.; Zoli, M.; Clementi, F. Brain nicotinic acetylcholine receptors: native subtypes and their relevance. Trends Pharmacol. Sci., 2006, 27, 482-491.
121. McGehee, D.S.; Role, L.W. Physiological diversity of nicotinic acetylcholine receptors expressed by vertebrate neurons. Annu. Rev. Physiol., 1995, 57, 521-546.
122. D'Hoedt, D.; Bertrand, D. Nicotinic acetylcholine receptors: an overview on drug discovery. Expert Opin. Ther. Targets, 2009, 13, 395-411.
123. Gotti, C.; Clementi, F. Neuronal nicotinic receptors: from structure to pathology. Prog. Neurobiol., 2004, 74, 363-396.
124. Dani, J.A.; Bertrand, D. Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system. Annu. Rev. Pharmacol. Toxicol., 2007, 47, 699-729.
125. Vazquez-Palacios, G.; Bonilla-Jaime, H. Nicotine acetylcholine receptors and neuropsychiatric disorders. Rev. Neurol., 2004, 39, 1146-1160.
126. Blomqvist, O.; Engel, J.A.; Nissbrandt, H.; Soderpalm, B. The mesolimbic dopamine-activating properties of ethanol are antagonized by mecamylamine. Eur. J. Pharmacol., 1993, 249, 207-213.
127. Blomqvist, O.; Ericson, M.; Engel, J.A.; Soderpalm, B. Accumbal dopamine overflow after ethanol: localization of the antagonizing effect of mecamylamine. Eur. J. Pharmacol., 1997, 334, 149-156.
128. Brodie, M.S.; Pesold, C.; Appel, S.B. Ethanol directly excites dopaminergic ventral tegmental area reward neurons. Alcohol. Clin. Exp. Res., 1999, 23, 1848-1852.
129. Clarke, P.B.; Fu, D.S.; Jakubovic, A.; Fibiger, H.C. Evidence that mesolimbic dopaminergic activation underlies the locomotor stimulant action of nicotine in rats. J. Pharmacol. Exp. Ther., 1988, 246, 701-708.
130. Imperato, A.; Mulas, A.; Di Chiara, G. Nicotine preferentially stimulates dopamine release in the limbic system of freely moving rats. Eur. J. Pharmacol., 1986, 132, 337-338.
131. Larsson, A.; Edstrom, L.; Svensson, L.; Soderpalm, B.; Engel, J.A. Voluntary ethanol intake increases extracellular acetylcholine levels in the ventral tegmental area in the rat. Alcohol Alcohol., 2005, 40, 349-358.
132. Ericson, M.; Molander, A.; Lof, E.; Engel, J.A.; Soderpalm, B. Ethanol elevates accumbal dopamine levels via indirect activation of ventral tegmental nicotinic acetylcholine receptors. Eur. J. Pharmacol., 2003, 467, 85-93.
133. Larsson, A.; Svensson, L.; Soderpalm, B.; Engel, J.A. Role of different nicotinic acetylcholine receptors in mediating behavioral and neurochemical effects of ethanol in mice. Alcohol, 2002, 28, 157-167.
134. Larsson, A.; Jerlhag, E.; Svensson, L.; Soderpalm, B.; Engel, J.A. Is an alpha-conotoxin MII-sensitive mechanism involved in the neurochemical, stimulatory, and rewarding effects of ethanol? Alcohol, 2004, 34, 239-250.
135. Crawley, J.N.; Belknap, J.K.; Collins, A.; Crabbe, J.C.; Frankel, W.; Henderson, N.; Hitzemann, R.J.; Maxson, S.C.; Miner, L.L.; Silva, A.J.; Wehner, J.M.; Wynshaw-Boris, A.; Paylor, R. Behavioral phenotypes of inbred mouse strains: implications and recommendations for molecular studies. Psychopharmacology (Berl)., 1997, 132, 107-124.
136. 2-subunit to the behavioural effects of nicotine. Biochem. Soc. Trans., 1997, 25, 824-829.
137. Tapper, A.R.; McKinney, S.L.; Nashmi, R.; Schwarz, J.; Deshpande, P.; Labarca, C.; Whiteaker, P.; Marks, M.J.; Collins, A.C.; Lester, H.A. Nicotine activation of a4* receptors: sufficient for reward, tolerance, and sensitization. Science, 2004, 306, 1029-1032.
138. Grant, K.A. Emerging neurochemical concepts in the actions of ethanol at ligand-gated ion channels. Behav. Pharmacol., 1994, 5, 383-404.
139. Lovinger, D.M. Alcohols and neurotransmitter gated ion channels: past, present and future. Naunyn-Schmiedebergs Arch. Pharmacol., 1997, 356, 267-282.
140. Cott, J.; Carlsson, A.; Engel, J.; Lindqvist, M. Suppression of ethanol-induced locomotor stimulation by GABA-like drugs. Naunyn- Schmiedebergs Arch. Pharmacol. 1976, 295, 203-209.
141. Liljequist, S.; Engel, J. Effects of GABAergic agonists and antagonists on various ethanol-induced behavioral changes. Psychopharmacology (Berl), 1982, 78, 71-75.
142. Allan, A.M.; Harris, R.A. Gamma-aminobutyric acid and alcohol actions: neurochemical studies of long sleep and short sleep mice. Life Sci., 1986, 39, 2005-2015.
143. Suzdak, P.D.; Schwartz, R.D.; Skolnick, P.; Paul, S.M. Ethanol stimulates gamma-aminobutyric acid receptor-mediated chloride transport in rat brain synaptoneurosomes. Proc. Natl. Acad. Sci. USA, 1986, 83, 4071-4075.
144. 36Cl-influx in primary spinal cord cultured neurons. Brain Res. Bull., 1986, 17, 123-126.
145. Lovinger, D.M.; White, G.; Weight, F.F. Ethanol inhibits NMDA-activated ion current in hippocampal neurons. Science, 1989, 243, 1721-1724.
146. 3 receptor-mediated ion current in neuroblastoma cells and isolated adult mammalian neurons. Mol. Pharmacol., 1991, 40, 263-270.
147. Engblom, A.C.; Akerman, K.E. Effect of ethanol on gamma-aminobutyric acid and glycine receptor-coupled Cl- fluxes in rat brain synaptoneurosomes. J. Neurochem., 1991, 57, 384-390.
148. Forman, S.A.; Righi, D.L.; Miller, K.W. Ethanol increases agonist affinity for nicotinic receptors from Torpedo. Biochim. Biophys. Acta, 1989, 987, 95-103.
149. Ei-Fakahany, E.F.; Miller, E.R.; Abbassy, M.A.; Eldefrawi, A.T.; Eldefrawi, M.E. Alcohol modulation of drug binding to the channel sites of the nicotinic acetylcholine receptor. J. Pharmacol. Exp. Ther., 1983, 224, 289-296.
150. Wu, G.; Tonner, P.H.; Miller, K.W. Ethanol stabilizes the open channel state of the Torpedo nicotinic acetylcholine receptor. Mol. Pharmacol., 1994, 45, 102-108.
151. Blomqvist, O.; Soderpalm, B.; Engel, J.A. Ethanol-induced locomotor activity: involvement of central nicotinic acetylcholine receptors? Brain Res. Bull., 1992, 29, 173-178.
152. Shytle, R.D.; Penny, E.; Silver, A.A.; Goldman, J.; Sanberg, P.R. Mecamylamine (Inversine): an old antihypertensive with new research directions. J. Hum. Hypertens., 2002, 16, 453-457.
153. Cardoso, R.A.; Brozowski, S.J.; Chavez-Noriega, L.E.; Harpold, M.; Valenzuela, C.F.; Harris, R.A. Effects of ethanol on recombinant human neuronal nicotinic acetylcholine receptors expressed in Xenopus oocytes. J. Pharmacol. Exp. Ther., 1999, 289, 774-780.
154. 7 receptors involves the amino-terminal domain of the receptor. Mol. Pharmacol., 1996, 50, 1010-1016.
155. Nagata, K.; Aistrup, G.L.; Huang, C.S.; Marszalec, W.; Song, J.H.; Yeh, J.Z.; Narahashi, T. Potent modulation of neuronal nicotinic acetylcholine receptor-channel by ethanol. Neurosci. Lett., 1996, 217, 189-193.
156. Brodie, M. S.; Shefner, S. A.; Dunwiddie, T. V. Ethanol increases the firing rate of dopamine neurons of the rat ventral tegmental area in vitro. Brain Res. 1990, 508, 65-69.
157. Brodie, M.S.; Appel, S.B. Dopaminergic neurons in the ventral tegmental area of C57BL/6J and DBA/2J mice differ in sensitivity to ethanol excitation. Alcohol. Clin. Exp. Res., 2000, 24, 1120-1124.
158. Majchrowicz, E.; Hunt, W.A. Temporal relationship of the induction of tolerance and physical dependence after continuous intoxication with maximum tolerable doses of ethanol in rats. Psychopharmacology (Berl), 1976, 50, 107-112.
159. Simms, J.A.; Steensland, P.; Medina, B.; Abernathy, K.E.; Chandler, L.J.; Wise, R.; Bartlett, S.E. Intermittent access to 20% ethanol induces high ethanol consumption in Long-Evans and Wistar rats. Alcohol. Clin. Exp. Res., 2008, 32, 1816-1823.
160. Bell, R.L.; Rodd, Z.A.; Lumeng, L.; Murphy, J.M.; McBride, W.J. The alcohol-preferring P rat and animal models of excessive alcohol drinking. Addict. Biol., 2006, 11, 270-288.
161. Kuzmin, A.; Jerlhag, E.; Liljequist, S.; Engel, J. Effects of subunit selective nACh receptors on operant ethanol self-administration and relapse-like ethanol-drinking behavior. Psychopharmacology (Berl), 2009, 203, 99-108.
162. Stolerman, I.P.; Chandler, C.J.; Garcha, H.S.; Newton, J.M. Selective antagonism of behavioural effects of nicotine by dihydro-b-erythroidine in rats. Psychopharmacology (Berl), 1997, 129, 390-397.
163. Curzon, P.; Brioni, J.D.; Decker, M.W. Effect of intraventricular injections of dihydro-beta-erythroidine (DHbE) on spatial memory in the rat. Brain Res., 1996, 714, 185-191.
164. Picciotto, M.R.; Zoli, M.; Rimondini, R.; Lena, C.; Marubio, L.M.; Pich, E.M.; Fuxe, K.; Changeux, J.P. Acetylcholine receptors containing the b2 subunit are involved in the reinforcing properties of nicotine. Nature, 1998, 391, 173-177.
165. Whiteaker, P.; Marks, M.J.; Grady, S.R.; Lu, Y.; Picciotto, M.R.; Changeux, J.P.; Collins, A.C. Pharmacological and null mutation approaches reveal nicotinic receptor diversity. Eur. J. Pharmacol., 2000, 393, 123-135.
166. 6 subunit-containing nicotinic acetylcholine receptors. J. Neurosci., 2003, 23, 8445-8452.
167. Jerlhag, E.; Grotli, M.; Luthman, K.; Svensson, L.; Engel, J.A. Role of the subunit composition of central nicotinic acetylcholine receptors for the stimulatory and dopamine-enhancing effects of ethanol. Alcohol Alcohol., 2006, 41, 486-493.
168. Samson, H.H. Initiation of ethanol reinforcement using a sucrose-substitution procedure in food- and water-sated rats. Alcohol. Clin. Exp. Res., 1986, 10, 436-442.
169. Meisch, R.A.; Thompson, T. Ethanol intake during schedule-induced polydipsia. Physiol. Behav., 1972, 8, 471-475.
170. Sinclair, J.D.; Hyytia, P.; Nurmi, M. The limited access paradigm: description of one method. Alcohol, 1992, 9, 441-444.
171. Wayner, M.J.; Greenberg, I. Effects of hypothalamic stimulation, acclimation and periodic withdrawal on ethanol consumption. Physiol. Behav., 1972, 9, 737-740.
172. Cicero, T.J.; Myers, R.D. Selection of a single ethanol test solution in free-choice studies with animals. Q. J. Stud. Alcohol., 1968, 29, 446-448.
173. Kiefer, S.W.; Bice, P.J.; Badia-Elder, N. Alterations in taste reactivity to alcohol in rats given continuous alcohol access followed by abstinence. Alcohol. Clin. Exp. Res., 1994, 18, 555-559.
174. Eriksson, K. Genetic selection for voluntary alcohol consumption in the albino rat. Science, 1968, 159, 739-741.
175. Li, T.K.; Lumeng, L.; McBride, W.J.; Murphy, J.M. Rodent lines selected for factors affecting alcohol consumption. Alcohol Alcohol. Suppl., 1987, 1, 91-96.
176. Mardones, J.; Segovia-Riquelme, N. Thirty-two years of selection of rats by ethanol preference: UChA and UChB strains. Neurobehav. Toxicol. Teratol., 1983, 5, 171-178.
177. Wise, R.A. Voluntary ethanol intake in rats following exposure to ethanol on various schedules. Psychopharmacologia, 1973, 29, 203-210.
178. Pinel, J.P.; Huang, E. Effects of periodic withdrawal on ethanol and saccharin selection in rats. Physiol. Behav., 1976, 16, 693-698.
179. Tomie, A.; Miller, W.C.; Dranoff, E.; Pohorecky, L.A. Intermittent presentations of ethanol sipper tube induce ethanol drinking in rats. Alcohol Alcohol., 2006, 41, 225-230.
180. Tomie, A.; di Poce, J.; Derenzo, C.C.; Pohorecky, L.A. Autoshaping of ethanol drinking: an animal model of binge drinking. Alcohol Alcohol., 2002, 37, 138-146.
181. 2 nicotinic receptor partial agonist for smoking cessation. J. Med. Chem., 2005, 48, 3474-3477.
182. 2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology, 2007, 52, 985-994.
183. 2 nAChR partial agonist varenicline related to effects on reward, mood and cognition. Biochem. Pharmacol., 2009, 78, 813-824.
184. Gulick, D.; Gould, T.J. Varenicline ameliorates ethanol-induced deficits in learning in C57BL/6 mice. Neurobiol. Learn. Mem., 2008, 90, 230-236.
185. 4 nicotinic receptors as a strategy to reduce opioid and stimulant self-administration. Eur. J. Pharmacol., 2002, 438, 99-105.
186. Rezvani, A.H.; Overstreet, D.H.; Yang, Y.; Maisonneuve, I.M.; Bandarage, U.K.; Kuehne, M.E.; Glick, S.D. Attenuation of alcohol consumption by a novel nontoxic ibogaine analogue (18-methoxycoronaridine) in alcohol-preferring rats. Pharmacol. Biochem. Behav., 1997, 58, 615-619.
187. Glick, S.D.; Maisonneuve, I.M.; Kitchen, B.A. Modulation of nicotine self-administration in rats by combination therapy with agents blocking a3b4 nicotinic receptors. Eur. J. Pharmacol., 2002, 448, 185-191.
188. Glick, S.D.; Maisonneuve, I.M. Development of novel medications for drug addiction: the legacy of an African shrub. Ann. NY Acad. Sci., 2000, 909, 88-103.
189. 4 subtypes in rat tissues by autoradiography. J. Neurochem., 2002, 82, 468-481.
190. 3 subunit in central nicotinic binding populations. J. Neurosci., 2002, 22, 2522-2529.
191. 2 neuronal nicotinic receptor subunit mRNAs in the central nervous system: a hybridization histochemical study in the rat. J. Comp. Neurol., 1989, 284, 314-335.
192. 4. Neuron, 1989, 3, 487-496.
193. Mulle, C.; Changeux, J.P. A novel type of nicotinic receptor in the rat central nervous system characterized by patch-clamp techniques. J. Neurosci., 1990, 10, 169-175.
194. 4, expressed in transfected eucaryotic cells. Mol. Brain Res., 1995, 28, 101-109.
195. Lester, R.A.; Dani, J.A. Acetylcholine receptor desensitization induced by nicotine in rat medial habenula neurons. J. Neurophysiol., 1995, 74, 195-206.
196. Matsumoto, M.; Hikosaka, O. Lateral habenula as a source of negative reward signals in dopamine neurons. Nature, 2007, 447, 1111-1115.
197. Ullsperger, M.; von Cramon, D.Y. Error monitoring using external feedback: specific roles of the habenular complex, the reward system, and the cingulate motor area revealed by functional magnetic resonance imaging. J. Neurosci., 2003, 23, 4308-4314.
198. Lisoprawski, A.; Herve, D.; Blanc, G.; Glowinski, J.; Tassin, J.P. Selective activation of the mesocortico-frontal dopaminergic neurons induced by lesion of the habenula in the rat. Brain Res., 1980, 183, 229-234.
199. Sutherland, R.J.; Nakajima, S. Self-stimulation of the habenular complex in the rat. J. Comp. Physiol. Psychol., 1981, 95, 781-791.
200. Sasaki, K.; Suda, H.; Watanabe, H.; Yagi, H. Involvement of the entopeduncular nucleus and the habenula in methamphetamine-induced inhibition of dopamine neurons in the substantia nigra of rats. Brain Res. Bull., 1990, 25, 121-127.
201. Araki, M.; McGeer, P.L.; McGeer, E.G. Retrograde HRP tracing combined with a pharmacohistochemical method for GABA transaminase for the identification of presumptive GABAergic projections to the habenula. Brain Res., 1984, 304, 271-277.
202. Herkenham, M.; Nauta, W.J. Efferent connections of the habenular nuclei in the rat. J. Comp. Neurol., 1979, 187, 19-47.
203. Phillipson, O.T.; Griffiths, A.C. The topographic order of inputs to nucleus accumbens in the rat. Neuroscience, 1985, 16, 275-296.
204. Nishikawa, T.; Fage, D.; Scatton, B. Evidence for, and nature of, the tonic inhibitory influence of habenulointerpeduncular pathways upon cerebral dopaminergic transmission in the rat. Brain Res., 1986, 373, 324-336.
205. Sutherland, R.J. The dorsal diencephalic conduction system: a review of the anatomy and functions of the habenular complex. Neurosci. Biobehav. Rev., 1982, 6, 1-13.
206. Lecourtier, L.; Kelly, P.H. A conductor hidden in the orchestra? Role of the habenular complex in monoamine transmission and cognition. Neurosci. Biobehav. Rev., 2007, 31, 658-672.
207. Beckstead, R.M.; Domesick, V.B.; Nauta, W.J. Efferent connections of the substantia nigra and ventral tegmental area in the rat. Brain Res., 1979, 175, 191-217.
208. Martin, B.R.; Onaivi, E.S.; Martin, T.J. What is the nature of mecamylamine's antagonism of the central effects of nicotine? Biochem. Pharmacol., 1989, 38, 3391-3397.
209. Papke, R.L.; Sanberg, P.R.; Shytle, R.D. Analysis of mecamylamine stereoisomers on human nicotinic receptor subtypes. J. Pharmacol. Exp. Ther., 2001, 297, 646-656.
210. Young, E.M.; Mahler, S.; Chi, H.; de Wit, H. Mecamylamine and ethanol preference in healthy volunteers. Alcohol. Clin. Exp. Res., 2005, 29, 58-65.
211. Rose, J.E.; Sampson, A.; Levin, E.D.; Henningfield, J.E. Mecamylamine increases nicotine preference and attenuates nicotine discrimination. Pharmacol. Biochem. Behav., 1989, 32, 933-938.
212. Ericson, M.; Blomqvist, O.; Engel, J.A.; Soderpalm, B. Voluntary ethanol intake in the rat and the associated accumbal dopamine overflow are blocked by ventral tegmental mecamylamine. Eur. J. Pharmacol., 1998, 358, 189-196.
213. Blomqvist, O.; Hernandez-Avila, C.A.; Van Kirk, J.; Rose, J.E.; Kranzler, H.R. Mecamylamine modifies the pharmacokinetics and reinforcing effects of alcohol. Alcohol. Clin. Exp. Res., 2002, 26, 326-331.
214. Chi, H.; de Wit, H. Mecamylamine attenuates the subjective stimulant-like effects of alcohol in social drinkers. Alcohol. Clin. Exp. Res., 2003, 27, 780-786.
215. Newlin, D.B.; Thomson, J.B. Alcohol challenge with sons of alcoholics: a critical review and analysis. Psychol. Bull., 1990, 108, 383-402.
216. Newlin, D.B.; Thomson, J.B. Chronic tolerance and sensitization to alcohol in sons of alcoholics: II. Replication and reanalysis. Exp. Clin. Psychopharmacol., 1999, 7, 234-243.
217. Holm, K.J.; Spencer, C.M. Bupropion: a review of its use in the management of smoking cessation. Drugs, 2000, 59, 1007-1024.
218. Hurt, R.D.; Sachs, D.P.; Glover, E.D.; Offord, K.P.; Johnston, J.A.; Dale, L.C.; Khayrallah, M.A.; Schroeder, D.R.; Glover, P.N.; Sullivan, C.R.; Croghan, I.T.; Sullivan, P.M. A comparison of sustained-release bupropion and placebo for smoking cessation. N. Engl. J. Med., 1997, 337, 1195-1202.
219. Cryan, J.F.; Gasparini, F.; van Heeke, G.; Markou, A. Non-nicotinic neuropharmacological strategies for nicotine dependence: beyond bupropion. Drug Discov. Today, 2003, 8, 1025-1034.
220. 2 nicotinic receptor partial agonists for smoking cessation: carbon analogs of (-)-cytisine. Bioorg. Med. Chem. Lett., 2005, 15, 2974-2979.
221. 2 neuronal nicotinic receptor partial agonists for smoking cessation. Bioorg. Med. Chem. Lett., 2005, 15, 4889-4897.
222. McKee, S.A.; Harrison, E.L.; O'Malley, S.S.; Krishnan-Sarin, S.; Shi, J.; Tetrault, J.M.; Picciotto, M.R.; Petrakis, I.L.; Estevez, N.; Balchunas, E. Varenicline reduces alcohol self-administration in heavy-drinking smokers. Biol. Psychiatry, 2009, 66, 185-190.
223. O'Malley, S.S.; Krishnan-Sarin, S.; Farren, C.; Sinha, R.; Kreek, M.J. Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitary- adrenocortical axis. Psychopharmacology (Berl), 2002, 160, 19-29.
224. Kuehn, B.M. Studies linking smoking-cessation drug with suicide risk spark concerns. JAMA, 2009, 301, 1007-1008.
225. Stapleton, J.A.; Watson, L.; Spirling, L.I.; Smith, R.; Milbrandt, A.; Ratcliffe, M.; Sutherland, G. Varenicline in the routine treatment of tobacco dependence: a pre-post comparison with nicotine replacement therapy and an evaluation in those with mental illness. Addiction, 2008, 103, 146-154.
226. Oslin, D.W.; Berrettini, W.; Kranzler, H.R.; Pettinati, H.; Gelernter, J.; Volpicelli, J. R.; O'Brien, C.P. A functional polymorphism of the m-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology, 2003, 28, 1546-1552.
227. Mattson, M.E.; Litten, R.Z. Combining treatments for alcoholism: why and how? J. Stud. Alcohol Suppl., 2005, 8-16.
228. Kranzler, H.R.; Van Kirk, J. Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis. Alcohol. Clin. Exp. Res., 2001, 25, 1335-1341.
229. Mann, K.; Lehert, P.; Morgan, M.Y. The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: results of a meta-analysis. Alcohol. Clin. Exp. Res., 2004, 28, 51-63.
230. Mason, B. J. Acamprosate in the treatment of alcohol dependence. Expert Opin. Pharmacother., 2005, 6, 2103-2115.
231. Mason, B.J.; Goodman, A.M.; Chabac, S.; Lehert, P. Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: the role of patient motivation. J. Psychiatr. Res., 2006, 40, 383-393.
232. Mason, B.J.; Ownby, R.L. Acamprosate for the treatment of alcohol dependence: a review of double-blind, placebo-controlled trials. CNS Spectr., 2000, 5, 58-69.
233. Anton, R.F.; O'Malley, S.S.; Ciraulo, D.A.; Cisler, R.A.; Couper, D.; Donovan, D. M.; Gastfriend, D.R.; Hosking, J.D.; Johnson, B.A.; LoCastro, J.S.; Longabaugh, R.; Mason, B.J.; Mattson, M.E.; Miller, W.R.; Pettinati, H.M.; Randall, C.L.; Swift, R.; Weiss, R.D.; Williams, L.D.; Zweben, A. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study - a randomized controlled trial. JAMA, 2006, 295, 2003-2017.
234. Heinala, P.; Alho, H.; Kiianmaa, K.; Lonnqvist, J.; Kuoppasalmi, K.; Sinclair, J.D. Targeted use of naltrexone without prior detoxification in the treatment of alcohol dependence: a factorial double-blind, placebo-controlled trial. J. Clin. Psychopharmacol., 2001, 21, 287-292.
235. O'Malley, S.S.; Jaffe, A.J.; Chang, G.; Schottenfeld, R.S.; Meyer, R.E.; Rounsaville, B. Naltrexone and coping skills therapy for alcohol dependence. A controlled study. Arch. Gen. Psychiatr., 1992, 49, 881-887.
236. Balldin, J.; Berglund, M.; Borg, S.; Mansson, M.; Bendtsen, P.; Franck, J.; Gustafsson, L.; Halldin, J.; Nilsson, L.H.; Stolt, G.; Willander, A. A 6-month controlled naltrexone study: combined effect with cognitive behavioral therapy in outpatient treatment of alcohol dependence. Alcohol. Clin. Exp. Res., 2003, 27, 1142-1149.
237. O'Malley, S.S.; Rounsaville, B.J.; Farren, C.; Namkoong, K.; Wu, R.; Robinson, J.; O'Connor, P.G. Initial and maintenance naltrexone treatment for alcohol dependence using primary care vs specialty care: a nested sequence of 3 randomized trials. Arch. Intern. Med., 2003, 163, 1695-1704.
238. Donovan, D.M.; Anton, R.F.; Miller, W.R.; Longabaugh, R.; Hosking, J.D.; Youngblood, M. Combined pharmacotherapies and behavioral interventions for alcohol dependence (The COMBINE Study): examination of posttreatment drinking outcomes. J. Stud. Alcohol Drugs, 2008, 69, 5-13.
239. George, D.T.; Gilman, J.; Hersh, J.; Thorsell, A.; Herion, D.; Geyer, C.; Peng, X.; Kielbasa, W.; Rawlings, R.; Brandt, J.E.; Gehlert, D.R.; Tauscher, J.T.; Hunt, S.P.; Hommer, D.; Heilig, M. Neurokinin 1 receptor antagonism as a possible therapy for alcoholism. Science, 2008, 319, 1536-1539.
240. Johnson, B.A.; Ait-Daoud, N.; Prihoda, T.J. Combining ondansetron and naltrexone effectively treats biologically predisposed alcoholics: from hypotheses to preliminary clinical evidence. Alcohol. Clin. Exp. Res., 2000, 24, 737-742.
241. Swift, R.M.; Davidson, D.; Whelihan, W.; Kuznetsov, O. Ondansetron alters human alcohol intoxication. Biol. Psychiatr., 1996, 40, 514-521.
242. Kiefer, F.; Jahn, H.; Tarnaske, T.; Helwig, H.; Briken, P.; Holzbach, R.; Kampf, P.; Stracke, R.; Baehr, M.; Naber, D.; Wiedemann, K. Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch. Gen. Psychiatr., 2003, 60, 92-99.
243. Johnson, B.A.; O'Malley, S.S.; Ciraulo, D.A.; Roache, J.D.; Chambers, R.A.; Sarid-Segal, O.; Couper, D. Dose-ranging kinetics and behavioral pharmacology of naltrexone and acamprosate, both alone and combined, in alcohol-dependent subjects. J. Clin. Psychopharmacol., 2003, 23, 281-293.
244. Pettinati, H.M.; Weiss, R.D.; Dundon, W.; Miller, W.R.; Donovan, D.; Ernst, D.B.; Rounsaville, B.J. A structured approach to medical management: a psychosocial intervention to support pharmacotherapy in the treatment of alcohol dependence. J. Stud. Alcohol Suppl., 2005, 150, 170-178.
245. Kuehn, B.M. Varenicline gets stronger warnings about psychiatric problems, vehicle crashes. JAMA, 2009, 302, 834.
246. McClure, J.B.; Swan, G.E.; Jack, L.; Catz, S.L.; Zbikowski, S.M.; McAfee, T.A.; Deprey, M.; Richards, J.; Javitz, H. Mood, side-effects and smoking outcomes among persons with and without probable lifetime depression taking varenicline. J. Gen. Int. Med., 2009, 24, 563-569.
247. Kintz, P.; Evans, J.; Villain, M.; Cirimele, V. Smoking cessation with varenicline: a suicidal fatality. J. Anal. Toxicol., 2009, 33, 118-120.
248. Purvis, T.L.; Mambourg, S.E.; Balvanz, T.M.; Magallon, H.E.; Pham, R.H. Safety and effectiveness of varenicline in a veteran population with a high prevalence of mental illness. Ann. Pharmacother., 2009, 43, 862-867.
249. Kasliwal, R.; Wilton, L.V.; Shakir, S.A. Safety and drug utilization profile of varenicline as used in general practice in England: interim results from a prescription-event monitoring study. Drug Saf., 2009, 32, 499-507.
250. Hays, J.T. The risk-benefit balance of varenicline for smoking cessation. J. Thorac. Oncol., 2008, 3, 949-950.
251. Stapleton, J. Do the 10 UK suicides among those taking the smoking cessation drug varenicline suggest a causal link? Addiction, 2009, 104, 864-865.
252. Gunnell, D.; Irvine, D.; Wise, L.; Davies, C.; Martin, R.M. Varenicline and suicidal behaviour: a cohort study based on data from the general practice research database. BMJ, 2009, 339, b3805.
253. Ramon, J.M.; Bruguera, E. Real world study to evaluate the effectiveness of varenicline and cognitive-behavioural interventions for smoking cessation. Intl. J. Environ. Res. Public Health, 2009, 6, 1530-1538.
254. Grosshans, M.; Mutschler, J.; Hermann, D.; Mann, K.; Diehl, A. Reduced affective symptoms during tobacco dependence treatment with varenicline. Addiction, 2009, 104, 859-861.
255. Philip, N.S.; Carpenter, L.L.; Tyrka, A.R.; Whiteley, L.B.; Price, L.H. Varenicline augmentation in depressed smokers: an 8-week, open-label study. J. Clin. Psychiatr., 2009, 70, 1026-1031.
256. Ochoa, E.L. Varenicline reduced smoking behaviour in a mentally ill person. J. Psychopharmacol., 2009, 23, 340-341.
257. Smith, R.C.; Lindenmayer, J.P.; Davis, J.M.; Cornwell, J.; Noth, K.; Gupta, S.; Sershen, H.; Lajtha, A. Cognitive and antismoking effects of varenicline in patients with schizophrenia or schizoaffective disorder. Schizophr. Res., 2009, 110, 149-155.
258. Bechara, A. Decision making, impulse control and loss of willpower to resist drugs: a neurocognitive perspective. Nat. Neurosci., 2005, 8, 1458-1463.
259. Clark, L.; Robbins, T. Decision-making deficits in drug addiction. Trends Cogn. Sci., 2002, 6, 361.
260. Stalnaker, T.A.; Roesch, M.R.; Franz, T.M.; Burke, K.A.; Schoenbaum, G. Abnormal associative encoding in orbitofrontal neurons in cocaine-experienced rats during decision-making. Eur. J. Neurosci., 2006, 24, 2643-2653.
261. Moselhy, H.F.; Georgiou, G.; Kahn, A. Frontal lobe changes in alcoholism: a review of the literature. Alcohol Alcohol., 2001, 36, 357-368.
262. Glass, J.M.; Buu, A.; Adams, K.M.; Nigg, J.T.; Puttler, L.I.; Jester, J.M.; Zucker, R.A. Effects of alcoholism severity and smoking on executive neurocognitive function. Addiction, 2009, 104, 38-48.
263. Davies, S.J.; Pandit, S.A.; Feeney, A.; Stevenson, B.J.; Kerwin, R.W.; Nutt, D.J.; Marshall, E.J.; Boddington, S.; Lingford-Hughes, A. Is there cognitive impairment in clinically 'healthy' abstinent alcohol dependence? Alcohol Alcohol., 2005, 40, 498-503.
264. Loeber, S.; Duka, T.; Welzel, H.; Nakovics, H.; Heinz, A.; Flor, H.; Mann, K. Impairment of cognitive abilities and decision making after chronic use of alcohol: the impact of multiple detoxifications. Alcohol Alcohol., 2009, 44, 372-381.
265. London, E.D.; Ernst, M.; Grant, S.; Bonson, K.; Weinstein, A. Orbitofrontal cortex and human drug abuse: functional imaging. Cereb. Cortex, 2000, 10, 334-342.
266. Mazas, C.A.; Finn, P.R.; Steinmetz, J.E. Decision-making biases, antisocial personality, and early-onset alcoholism. Alcohol. Clin. Exp. Res., 2000, 24, 1036-1040.
267. Schoenbaum, G.; Setlow, B.; Saddoris, M.P.; Gallagher, M. Encoding predicted outcome and acquired value in orbitofrontal cortex during cue sampling depends upon input from basolateral amygdala. Neuron, 2003, 39, 855-867.
268. Crombag, H.S.; Gorny, G.; Li, Y.; Kolb, B.; Robinson, T.E. Opposite effects of amphetamine self-administration experience on dendritic spines in the medial and orbital prefrontal cortex. Cereb. Cortex, 2005, 15, 341-348.
269. Fein, G.; Bachman, L.; Fisher, S.; Davenport, L. Cognitive impairments in abstinent alcoholics. West. J. Med., 1990, 152, 531-537.
270. Chanraud, S.; Martelli, C.; Delain, F.; Kostogianni, N.; Douaud, G.; Aubin, H.J.; Reynaud, M.; Martinot, J.L. Brain morphometry and cognitive performance in detoxified alcohol-dependents with preserved psychosocial functioning. Neuropsychopharmacology, 2007, 32, 429-438.
271. Dom, G.; De Wilde, B.; Hulstijn, W.; van den Brink, W.; Sabbe, B. Decision-making deficits in alcohol-dependent patients with and without comorbid personality disorder. Alcohol. Clin. Exp. Res., 2006, 30, 1670-1677.
272. Bechara, A.; Damasio, A.R.; Damasio, H.; Anderson, S.W. Insensitivity to future consequences following damage to human prefrontal cortex. Cognition, 1994, 50, 7-15.
273. Bechara, A.; Dolan, S.; Denburg, N.; Hindes, A.; Anderson, S.W.; Nathan, P.E. Decision-making deficits, linked to a dysfunctional ventromedial prefrontal cortex, revealed in alcohol and stimulant abusers. Neuropsychologia, 2001, 39, 376-389.
274. Bechara, A.; Damasio, H. Decision-making and addiction (part I): impaired activation of somatic states in substance dependent individuals when pondering decisions with negative future consequences. Neuropsychologia, 2002, 40, 1675-1689.
275. Fein, G.; Klein, L.; Finn, P. Impairment on a simulated gambling task in long-term abstinent alcoholics. Alcohol. Clin. Exp. Res., 2004, 28, 1487-1491.
276. Fein, G.; Landman, B.; Tran, H.; McGillivray, S.; Finn, P.; Barakos, J.; Moon, K. Brain atrophy in long-term abstinent alcoholics who demonstrate impairment on a simulated gambling task. NeuroImage, 2006, 32, 1465-1471.
277. Bolla, K.I.; Eldreth, D.A.; London, E.D.; Kiehl, K.A.; Mouratidis, M.; Contoreggi, C.; Matochik, J.A.; Kurian, V.; Cadet, J.L.; Kimes, A.S.; Funderburk, F.R.; Ernst, M. Orbitofrontal cortex dysfunction in abstinent cocaine abusers performing a decision-making task. NeuroImage, 2003, 19, 1085-1094.
278. Rogers, R.D.; Everitt, B.J.; Baldacchino, A.; Blackshaw, A.J.; Swainson, R.; Wynne, K.; Baker, N.B.; Hunter, J.; Carthy, T.; Booker, E.; London, M.; Deakin, J.F.; Sahakian, B.J.; Robbins, T.W. Dissociable deficits in the decision-making cognition of chronic amphetamine abusers, opiate abusers, patients with focal damage to prefrontal cortex, and tryptophan-depleted normal volunteers: evidence for monoaminergic mechanisms. Neuropsychopharmacology, 1999, 20, 322-339.
279. Vassileva, J.; Petkova, P.; Georgiev, S.; Martin, E.M.; Tersiyski, R.; Raycheva, M.; Velinov, V.; Marinov, P. Impaired decision-making in psychopathic heroin addicts. Drug Alcohol Depend., 2007, 86, 287-289.
280. Whitlow, C.T.; Liguori, A.; Livengood, L.B.; Hart, S.L.; Mussat-Whitlow, B.J.; Lamborn, C.M.; Laurienti, P.J.; Porrino, L.J. Long-term heavy marijuana users make costly decisions on a gambling task. Drug Alcohol Depend., 2004, 76, 107-111.
281. Vanderschuren, L.J.; Everitt, B.J. Behavioral and neural mechanisms of compulsive drug seeking. Eur. J. Pharmacol., 2005, 526, 77-88.
282. Tapert, S.F.; Brown, S.A. Neuropsychological correlates of adolescent substance abuse: four-year outcomes. J. Int. Neuropsychol. Soc., 1999, 5, 481-493.
283. Mansvelder, H.D.; van Aerde, K. I.; Couey, J.J.; Brussaard, A.B. Nicotinic modulation of neuronal networks: from receptors to cognition. Psychopharmacology (Berl), 2006, 184, 292-305.
284. Levin, E.D.; McClernon, F.J.; Rezvani, A.H. Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization. Psychopharmacology (Berl), 2006, 184, 523-539.
285. Couey, J.J.; Meredith, R.M.; Spijker, S.; Poorthuis, R.B.; Smit, A.B.; Brussaard, A.B.; Mansvelder, H.D. Distributed network actions by nicotine increase the threshold for spike-timing-dependent plasticity in prefrontal cortex. Neuron, 2007, 54, 73-87.
286. Dunnett, S.B.; Everitt, B.J.; Robbins, T.W. The basal forebrain-cortical cholinergic system: interpreting the functional consequences of excitotoxic lesions. Trends Neurosci., 1991, 14, 494-501.
287. Everitt, B.J.; Robbins, T.W. Central cholinergic systems and cognition. Annu. Rev. Psychol., 1997, 48, 649-684.
288. Ochoa, E.L.; Lasalde-Dominicci, J. Cognitive deficits in schizophrenia: focus on neuronal nicotinic acetylcholine receptors and smoking. Cell. Mol. Neurobiol., 2007, 27, 609-639.
289. Levin, E.D. Nicotinic receptor subtypes and cognitive function. J. Neurobiol., 2002, 53, 633-640.
290. Zanardi, A.; Leo, G.; Biagini, G.; Zoli, M. Nicotine and neurodegeneration in ageing. Toxicol. Lett., 2002, 127, 207-215.
291. Levin, E.D.; Simon, B.B. Nicotinic acetylcholine involvement in cognitive function in animals. Psychopharmacology (Berl), 1998, 138, 217-230.
292. Allen, S.J.; MacGowan, S.H.; Tyler, S.; Wilcock, G.K.; Robertson, A.G.; Holden, P.H.; Smith, S.K.; Dawbarn, D. Reduced cholinergic function in normal and Alzheimer's disease brain is associated with apolipoprotein E4 genotype. Neurosci. Lett., 1997, 239, 33-36.
293. Tiraboschi, P.; Hansen, L.A.; Alford, M.; Masliah, E.; Thal, L.J.; Corey-Bloom, J. The decline in synapses and cholinergic activity is asynchronous in Alzheimer's disease. Neurology, 2000, 55, 1278-1283.
294. Geula, C.; Nagykery, N.; Nicholas, A.; Wu, C.K. Cholinergic neuronal and axonal abnormalities are present early in aging and in Alzheimer disease. J. Neuropathol. Exp. Neurol., 2008, 67, 309-318.
295. Sarter, M.; Parikh, V.; Howe, W.M. nAChR agonist-induced cognition enhancement: integration of cognitive and neuronal mechanisms. Biochem. Pharmacol., 2009, 78, 658-667.